and they are celgene, gilead, biogen idec and regeneron.ll four of these stocks have had amazing runs this year. i'm well aware of that and i've been recommending them aggressively for a long time on the show. i think they're fantastic. celgene is basically a three-legged stool of innovative drugs. first one is made of the multiple myeloma franchise, which is a derivative of a poison. a poisonous drug. this drug has a lot of room to grow, particularly in europe. the second leg is called apraxame. this is a potential blockbuster oncology drug that's approved for breast cancer and non-small cell lung cancer. celgene is seeking approval for pancreatic cancer. we know how difficult that one is, and metastatic melanoma, as well. the third leg is one no one's talking about, which is an immunology and inflammation drug that's still in development, which i think could be a breakout drug for rheumatoid arthritis, where there really is nothing good out there. plus celgene sells for 23% growth rate and it's ridiculous. if you look at 2013 and 2016. gi